Recent Updates
Recently added Catalysts

Coramitug

Phase 1

Transthyretin Amyloid Cardiomyopathy | Small molecule | Cardiovascular |Novo Nordisk A/S|Last Updated: Apr 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment14
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07448623A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.PHASE1 RECRUITING 14Mar 2, 2026Jul 25, 2028Apr 13, 20261 Netherlands
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mean Standard Uptake Value Ratio (SUVRmean) in myocardium
Day 1-day 8

Measured as ratio.

Net uptake rate constant (Ki) in myocardium
0 to 168 hours

Measured as milliliter per minute per centimeter cube (mL/min/cm\^3).

Change in SUVRmean in myocardium
From baseline to week 52 (day 364), or week 60 (day 420) if there is no uptake expected/observed when both unradiolabelled and radiolabelled compounds are administered together

Measured as percentage (%).

Secondary Endpoints
Maximum Plasma Concentration (Cmax)
0 to 168 hours
Time at which maximum plasma concentration is observed (Tmax)
0 to 168 hours
Area under the curve (AUC)
0 to 168 hours
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1EXPERIMENTALThe cohort includes participants that will be evaluated for the cardiac uptake of 89Zr coramitug.
Cohort 2EXPERIMENTALThe cohort includes participants to evaluate the sink effect (if observed in cohort 1) and also evaluate competitive binding between 89Zr-coramitug and different dose levels of coramitug.
Interventions
NameTypeDescription
CoramitugDRUGCoramitug will be administered intravenously
Unlock Study Design Details
Eligibility Criteria
Age Range60 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female. * Age greater than or equal to (≥) 60 years or a...

Countries:Netherlands
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07448623Status: NOT_YET_RECRUITING → RECRUITING
LOWMay 24, 2026NCT07448623studyFirstPostDate: changed